Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

I tried anti-obesity medication and these were the surprising side-effects' - When Henry Conway hit his forties his BMI ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

People today have many more options to help with obesity. If you are interested in trying an anti-obesity medication, talk with a doctor. GLP-1 drugs are becoming increasingly popular for their ...

Anti-obesity medication use was associated with reduced alcohol consumption among patients in a telehealth medical weight ...

Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.